SIXTH ALEXIS CARREL CONFERENCE ON CHRONIC REJECTION AND GRAFT ATHEROSCLEROSIS

The Sixth Alexis Carrel Conference will be held in Banff, Canada on December 4–7, 1996. The meeting is aimed at transplant physicians, surgeons, pathologists, and immunologists, as well as health care professionals with an interest in transplantation. For information regarding registration and abstracts, please contact the conference organizer: Dr. Leendert C. Paul, St. Michael’s Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada. Telephone: 416-867-3701; fax: 416-867-3709; e-mail: lpaul@utoronto.ca.

ADVANCED NEPHROLOGY: NEPHROLOGY FOR THE CONSULTANT

Advanced Nephrology: Nephrology for the Consultant, sponsored by the Division of Nephrology, Department of Medicine, University of California, San Diego, CA, will be held February 6-8, 1997, at The Hotel del Coronado, Coronado (San Diego), CA. The registration fee is $395 for physicians in practice, and $175 for residents/fellows. This course is designated for 17 hours of AMA Category I Accreditation. For information, contact Shirley Kolkey, Course Coordinator, at 1660 Hotel Circle North, #220, San Diego, CA 92108. Telephone: 619-299-6673; fax: 619-299-6675.

FIFTH BASIC SCIENCES SYMPOSIUM OF THE TRANSPANTATION SOCIETY

The Fifth Basic Sciences Symposium of the Transplantation Society will be held at the Chautauqua Institution, Chautauqua, NY, on September 6–11, 1997. Distinguished plenary speakers will update the most relevant topics of transplantation biology, which will be enhanced by oral and poster presentations by interested participants on the following subjects: T-Cell Stimulation and Co-stimulation, T-Cell Signalling Mechanisms, Immune Privilege, Tolerance, Chimerism and Bone Marrow Transplantation, Immunosuppression, Alloreactivity and Rejection, and Newer Experimental Models. Registration fees and costs of board and lodging have been kept to reasonable levels to encourage participation. The Chautauqua Institution has an esteemed historical, educational, and cultural tradition and is a splendid setting for a scholarly retreat, yet one within easy reach of Buffalo, NY. The deadline for submission of abstracts is January 31, 1997. For further information, contact R. Cunningham, Ph.D., The Ernest Witebsky Center for Immunology, School of Medicine and Biomedical Sciences, 233 Sherman Hall, 3435 Main Street, Buffalo, NY 14214-3078. Telephone: 716-829-2901; fax: 716/829-2158; email: reunning@ubmedb.buffalo.edu.
Classified Advertising Section

Line Rates: $110.00 for 50 words or less. Each additional word $2.20.

Display Rates:

<table>
<thead>
<tr>
<th>Page Size</th>
<th>Dimensions</th>
<th>Width</th>
<th>Height</th>
<th>1 times</th>
<th>2 times</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 page</td>
<td></td>
<td>7&quot;</td>
<td>10&quot;</td>
<td>$895</td>
<td>$870</td>
</tr>
<tr>
<td>1/2 page</td>
<td></td>
<td>7&quot;</td>
<td>5&quot;</td>
<td>$615</td>
<td>$595</td>
</tr>
<tr>
<td>1/4 page</td>
<td></td>
<td>3 1/2&quot;</td>
<td>5&quot;</td>
<td>$440</td>
<td>$430</td>
</tr>
<tr>
<td>1/8 page</td>
<td></td>
<td>3 1/2&quot;</td>
<td>2 1/2&quot;</td>
<td>$310</td>
<td>$300</td>
</tr>
</tbody>
</table>

Printing material: negatives, mechanicals or camera-ready copy. If you would like us to typeset your ad, there is an additional fee: 1/8 page - $25, 1/4 page - $45, 1/2 page - $60, full page - $85.

Terms: Ads must be prepaid or a purchase order must accompany ad copy before printing. A $20 charge will be added for the use of our box number.

* Credit will be granted to advertisers for errors Only when error would prevent applicant from contacting advertiser.

- Positions Open - Meetings
- Seminars - Fellowship Announcements
- Faculty Positions - Course Announcements

Deadline for Ad Placement

Journal of the American Society of Nephrology is published monthly. The deadline for ad placement is the 10th of the month prior to the month of issue.

For Information and Placement, Contact:

Michael Faulkner: 1-800-528-1843
Jason Pointe: 1-800-528-5660
Taron Butler: 1-800-645-3658
Our Fax #: (410) 528-4452
E-mail: mfaulkner@wwilkins.com
jpointe@wwilkins.com

Journal of the American Society of Nephrology
351 W. Camden Street-5N
Baltimore, Maryland 21201-2436
A UNIQUE HEMODYNAMIC AND SAFETY PROFILE DIFFERENT FROM DIHYDROPYRIDININES

Effective 24-hour control of hypertension or angina
- Reduces blood pressure with no reflex tachycardia
- Increases exercise tolerance, reduces vasospasm, and decreases heart rate in angina

Well tolerated control regardless of age or gender†
- A side-effect discontinuation rate comparable to placebo
- Most commonly reported side effects are headache (5.4%), bradycardia (3.3%), first-degree AV block (3.3%), dizziness (3.0%), edema (2.6%), ECG abnormality (1.6%), and asthenia (1.8%)†

True 24-hour control from a unique patented delivery system
- No other diltiazem is therapeutically equivalent to Cardizem CD‡

*Cardizem CD is a benzothiazepine calcium channel blocker.
† In clinical trials with Cardizem CD.
‡ FDA does not, at this time, consider other diltiazems to be therapeutically equivalent because bioequivalence has not been demonstrated through appropriate studies.

Please see brief summary of prescribing information on adjacent page.

FOR HYPERTENSION OR ANGINA

ONCE-A-DAY CARDIZEM® CD (diltiazem HCl) 120-, 180-, 240-, 300-mg Capsules

No other diltiazem is therapeutically equivalent‡
No other diltiazem is therapeutically equivalent.

The following table presents the most common adverse reactions reported in placebo-controlled angina and hypertension trials in patients receiving CARDIZEM CD up to 360 mg with rates in placebo patients shown for comparison.

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Cardizem CD (n=607)</th>
<th>Placebo (n=301)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>5.4%</td>
<td>5.0%</td>
</tr>
<tr>
<td>Dizziness</td>
<td>3.0%</td>
<td>3.0%</td>
</tr>
<tr>
<td>Bradycardia</td>
<td>3.3%</td>
<td>1.0%</td>
</tr>
<tr>
<td>AV Block/First Degree</td>
<td>3.0%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Edema</td>
<td>2.6%</td>
<td>1.3%</td>
</tr>
<tr>
<td>GI Abnormalities</td>
<td>1.6%</td>
<td>1.2%</td>
</tr>
<tr>
<td>Asthenia</td>
<td>1.8%</td>
<td>1.7%</td>
</tr>
</tbody>
</table>

In clinical trials of CARDIZEM CD capsules, CARDIZEM tablets, and CARDIZEM SR capsules involving over 3200 patients, the most common adverse reactions (greater than 1%) were edema (4.6%), headache (4.6%), dizziness (3.5%), asthenia (2.8%), first-degree AV block (2.4%), bradycardia (1.7%), flushing (1.4%), nausea (1.4%), and rash (1.2%).

In addition, the following events were reported infrequently (less than 1%): chest pain, vasomotor disturbances, nausea, vomiting, and weight increase.

Dermalrheum: Petechiae, photophobia, pruritus, urticaria.

Other Antagonists: CPN increase, dyspnea, epistaxis, eye irritation, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, oedema, otalgia, painful urination, polyuria, sexual difficulties.

The following postmarketing events have been reported infrequently in patients receiving CARDIZEM allergic reactions, anemia, angina pectoris (including fatal or precipitous death), atropine, dyspnea, edema, flushing, hypotension, hypotension, palpitation, syncope, tachycardia, ventricular extrasystoles.

Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, headache, insomnia, personality change, somnolence, tremor, twitching.

Gastrointestinal: Anorexia, constipation, diarrhea, dry mouth, dyspepsia, flatulence, gastritis, nausea, vomiting, weight increase.

Dermalrheum: Petechiae, photophobia, pruritus, urticaria.

Other Antagonists: CPN increase, dyspnea, epistaxis, eye irritation, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, oedema, otalgia, painful urination, polyuria, sexual difficulties.

The following postmarketing events have been reported infrequently in patients receiving CARDIZEM allergic reactions, anemia, angina pectoris (including fatal or precipitous death), atropine, dyspnea, edema, flushing, hypotension, hypotension, palpitation, syncope, tachycardia, ventricular extrasystoles.

Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, headache, insomnia, personality change, somnolence, tremor, twitching.

Gastrointestinal: Anorexia, constipation, diarrhea, dry mouth, dyspepsia, flatulence, gastritis, nausea, vomiting, weight increase.

Dermalrheum: Petechiae, photophobia, pruritus, urticaria.

Other Antagonists: CPN increase, dyspnea, epistaxis, eye irritation, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, oedema, otalgia, painful urination, polyuria, sexual difficulties.

The following postmarketing events have been reported infrequently in patients receiving CARDIZEM allergic reactions, anemia, angina pectoris (including fatal or precipitous death), atropine, dyspnea, edema, flushing, hypotension, hypotension, palpitation, syncope, tachycardia, ventricular extrasystoles.

Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, headache, insomnia, personality change, somnolence, tremor, twitching.

Gastrointestinal: Anorexia, constipation, diarrhea, dry mouth, dyspepsia, flatulence, gastritis, nausea, vomiting, weight increase.

Dermalrheum: Petechiae, photophobia, pruritus, urticaria.

Other Antagonists: CPN increase, dyspnea, epistaxis, eye irritation, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, oedema, otalgia, painful urination, polyuria, sexual difficulties.

The following postmarketing events have been reported infrequently in patients receiving CARDIZEM allergic reactions, anemia, angina pectoris (including fatal or precipitous death), atropine, dyspnea, edema, flushing, hypotension, hypotension, palpitation, syncope, tachycardia, ventricular extrasystoles.

Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, headache, insomnia, personality change, somnolence, tremor, twitching.

Gastrointestinal: Anorexia, constipation, diarrhea, dry mouth, dyspepsia, flatulence, gastritis, nausea, vomiting, weight increase.

Dermalrheum: Petechiae, photophobia, pruritus, urticaria.

Other Antagonists: CPN increase, dyspnea, epistaxis, eye irritation, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, oedema, otalgia, painful urination, polyuria, sexual difficulties.

The following postmarketing events have been reported infrequently in patients receiving CARDIZEM allergic reactions, anemia, angina pectoris (including fatal or precipitous death), atropine, dyspnea, edema, flushing, hypotension, hypotension, palpitation, syncope, tachycardia, ventricular extrasystoles.

Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, headache, insomnia, personality change, somnolence, tremor, twitching.

Gastrointestinal: Anorexia, constipation, diarrhea, dry mouth, dyspepsia, flatulence, gastritis, nausea, vomiting, weight increase.

Dermalrheum: Petechiae, photophobia, pruritus, urticaria.

Other Antagonists: CPN increase, dyspnea, epistaxis, eye irritation, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, oedema, otalgia, painful urination, polyuria, sexual difficulties.

The following postmarketing events have been reported infrequently in patients receiving CARDIZEM allergic reactions, anemia, angina pectoris (including fatal or precipitous death), atropine, dyspnea, edema, flushing, hypotension, hypotension, palpitation, syncope, tachycardia, ventricular extrasystoles.

Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, headache, insomnia, personality change, somnolence, tremor, twitching.

Gastrointestinal: Anorexia, constipation, diarrhea, dry mouth, dyspepsia, flatulence, gastritis, nausea, vomiting, weight increase.

Dermalrheum: Petechiae, photophobia, pruritus, urticaria.

Other Antagonists: CPN increase, dyspnea, epistaxis, eye irritation, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, oedema, otalgia, painful urination, polyuria, sexual difficulties.

The following postmarketing events have been reported infrequently in patients receiving CARDIZEM allergic reactions, anemia, angina pectoris (including fatal or precipitous death), atropine, dyspnea, edema, flushing, hypotension, hypotension, palpitation, syncope, tachycardia, ventricular extrasystoles.

Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, headache, insomnia, personality change, somnolence, tremor, twitching.

Gastrointestinal: Anorexia, constipation, diarrhea, dry mouth, dyspepsia, flatulence, gastritis, nausea, vomiting, weight increase.

Dermalrheum: Petechiae, photophobia, pruritus, urticaria.

Other Antagonists: CPN increase, dyspnea, epistaxis, eye irritation, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, oedema, otalgia, painful urination, polyuria, sexual difficulties.

The following postmarketing events have been reported infrequently in patients receiving CARDIZEM allergic reactions, anemia, angina pectoris (including fatal or precipitous death), atropine, dyspnea, edema, flushing, hypotension, hypotension, palpitation, syncope, tachycardia, ventricular extrasystoles.